Oruka Therapeutics (ORKA) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 235.3% versus a gain of 41.5%. Over five years, ORKA leads with a +145.3% price change compared with +96.8% for PHVS. Oruka Therapeutics is the larger company by market cap ($5.44 billion vs $2.18 billion), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | PHVS |
|---|---|---|
| Share price | $82.11 | $31.10 |
| Market cap | $5.44B | $2.18B |
| 1-day change | +6.25% | -0.06% |
| YTD return | +170.90% | +12.07% |
| 1-year return | +235.28% | +41.49% |
| 5-year return | +145.25% | +96.84% |
| EPS (TTM) | $-2.04 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-105.43M | $-25.99M |
| 52-week high | $115.52 | $43.25 |
| 52-week low | $24.46 | $20.65 |
| Distance from 52-week high | -28.92% | -28.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.77% | +84.47% |
| Average volume | 907.59K | 713.55K |
| Shares outstanding | 66.21M | 70.20M |
| Employees | 68 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 2.5 times larger than Pharvaris N.V. by market value ($5.44B vs $2.18B).
- ORKA has outperformed PHVS by 193.8 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
ORKA vs PHVS FAQ
Which is bigger, Oruka Therapeutics or Pharvaris N.V.?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.44B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, ORKA or PHVS?
ORKA returned +235.28% over the past 12 months, compared with +41.49% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Pharvaris N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Oruka Therapeutics and Biotechnology: Pharmaceutical Preparations for Pharvaris N.V..